Aducanumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | beta amyloid |
| Clinical data | |
| Other names | BIIB037 |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| Chemical and physical data | |
| Formula | C6472H10028N1740O2014S46 |
| Molar mass | 145.9 kg/mol g·mol−1 |
Aducanumab is a human monoclonal antibody that is being studied for the treatment of Alzheimer's disease (AD).[2] It is being developed by Biogen Inc., which licensed the drug candidate from Neurimmune, its discoverer.[3] The antibody targets aggregated forms of β-amyloid (Aβ) in the hopes of reducing its buildup.[4]
Research
Interim results from the second Phase 1 study of the drug were reported in March 2015.[2][5]
A phase Ib study was published in August 2016, based on one year of "monthly intravenous infusions" of aducanumab, with brain scans to measure amyloid plaques.[6] Phase 3 clinical trials are ongoing.[6]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ a b Cynthia Fox for Drug Discovery and Development (April 28, 2015). "The Story of Biogen's Alzheimer's Drug, Aducanumab".
- ^ Rebecca Zacks for Xconomy (November 20, 2007). "Biogen Inks $380 Million Deal with Swiss Company".
- ^ Toyn, Jeremy (2015). "What lessons can be learned from failed Alzheimer's disease trials?". Expert Rev. Clin. Pharmacol. 8 (3): 267–269. doi:10.1586/17512433.2015.1034690. PMID 25860157.
- ^ Matthew Herper for Forbes. March 20, 2015 Biogen Drug Could Inspire New Hope For Alzheimer's Treatments
- ^ a b Sevigny J.; Chiao P.; Bussière T.; Weinreb P.H.; Williams L.; Maier M.; Dunstan R.; Salloway S.; Chen T.; Ling Y.; O'Gorman J.; Qian F.; Arastu M.; Li M.; Chollate S.; Brennan M.S.; Quintero-Monzon O.; Scannevin R.H.; Arnold H.M.; Engber T.; Rhodes K.; Ferrero J.; Hang Y.; Mikulskis A.; Grimm J.; Hock C.; Nitsch R.M.; Sandrock A. (1 September 2016). "The antibody aducanumab reduces Aβ plaques in Alzheimer's disease". Nature. 537 (7618): 50–56. doi:10.1038/nature19323.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |